HilleVax, Inc. (NASDAQ:HLVX) Short Interest Down 6.3% in October

HilleVax, Inc. (NASDAQ:HLVX) saw a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,180,000 shares, a decrease of 6.3% from the October 15th total of 1,260,000 shares. Approximately 6.4% of the shares of the company are short sold. Based on an average daily trading volume, of 259,400 shares, the days-to-cover ratio is currently 4.5 days.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. EntryPoint Capital LLC purchased a new stake in shares of HilleVax in the 1st quarter valued at approximately $80,000. Tidal Investments LLC acquired a new position in shares of HilleVax in the first quarter valued at approximately $207,000. Maven Securities LTD purchased a new stake in HilleVax during the 2nd quarter worth approximately $217,000. BML Capital Management LLC acquired a new stake in HilleVax during the 3rd quarter worth approximately $35,000. Finally, Algert Global LLC purchased a new position in HilleVax in the 2nd quarter valued at approximately $519,000. Institutional investors and hedge funds own 86.42% of the company’s stock.

HilleVax Stock Performance

HLVX opened at $1.83 on Tuesday. HilleVax has a one year low of $1.55 and a one year high of $20.22. The business’s 50 day moving average price is $1.83 and its 200 day moving average price is $5.68.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.10). As a group, analysts predict that HilleVax will post -2.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price objective on shares of HilleVax in a report on Monday, August 12th. Six equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $3.00.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.